Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease

1Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

Abstract

The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly. There have recently been publications in the literature regarding the relationship between COVID-19 and Kawasaki disease, but there is no sufficient knowledge about the treatment and follow-up.

Author supplied keywords

References Powered by Scopus

Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

4115Citations
N/AReaders
Get full text

Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus

3348Citations
N/AReaders
Get full text

Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association

2702Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Lipid-Based Drug Delivery for Pneumonia Treatment

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Orbak, Z., Laloglu, F., & Akat, H. (2021). Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. Cardiology in the Young, 31(3), 507–510. https://doi.org/10.1017/S1047951120004291

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

68%

Researcher 5

20%

Lecturer / Post doc 2

8%

Professor / Associate Prof. 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

48%

Nursing and Health Professions 8

26%

Pharmacology, Toxicology and Pharmaceut... 6

19%

Biochemistry, Genetics and Molecular Bi... 2

6%

Save time finding and organizing research with Mendeley

Sign up for free